Back to Search
Start Over
A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19
- Source :
- Journal of Infection and Chemotherapy
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Introduction Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world. So far, no therapeutics have yet proven to be effective. Ribavirin was recommended for the treatment of COVID-19 in China because of its in vitro activity. However, evidence supporting its clinical use with good efficacy is still lacking. Methods A total of 208 confirmed severe COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and the length of hospital stay. Results 68 patients were treated with ribavirin while 140 not. There were no significant between-group differences in demographic characteristics, baseline laboratory test results, treatment, and distribution of ordinal scale scores at enrollment, except for coexisting diseases especially cancer (ribavirin group vs no ribavirin group, P = 0.01). Treatment with ribavirin was not associated with a difference in the time to clinical improvement (P = 0.48, HR = 0.88, 95% CI = 0.63–1.25). There were also no significant differences between-group in SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and the length of hospital stay. Conclusions In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment.
- Subjects :
- Male
0301 basic medicine
Microbiology (medical)
China
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030106 microbiology
medicine.disease_cause
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Ribavirin
medicine
Clinical endpoint
Humans
Pharmacology (medical)
030212 general & internal medicine
Clinical efficacy
Aged
Retrospective Studies
Coronavirus
SARS-CoV-2
business.industry
COVID-19
virus diseases
Cancer
Retrospective cohort study
Middle Aged
medicine.disease
COVID-19 Drug Treatment
Treatment Outcome
Infectious Diseases
chemistry
Original Article
Female
business
Subjects
Details
- ISSN :
- 1341321X
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Journal of Infection and Chemotherapy
- Accession number :
- edsair.doi.dedup.....b024f0c75eacacd5f0e8a662c458f20e